Replies to post #117378 on Biotech Values

[genisi]

On top of what you've mentioned, I also have confidence in management and their experience in bringing ERTs to the market. They need to enroll patients carefully as too severe ones will have advanced skeletal defects and will probably not improve on 6MWT during the trial. I don't see any reason why GALNS should have different injection site reactions than other ERTs.

I don't think PLX will spoil the nice statistics for ERT's to enter Phase 3, and will be approved :)

[ghmm]

I meant secondaries are significant if they are just trending I'd be concerned